Antimicrobial drug-induced thrombocytopenia: A review of the literature

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 8, 2012, Pages 818-829

  Loo, Angela S ^a   Gerzenshtein, Lana ^b   Ison, Michaelg ^c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

antimicrobials; coagulopathy; thrombocytopenia

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; PENTAMIDINE; PIPERACILLIN PLUS TAZOBACTAM; QUININE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; UNINDEXED DRUG; VALGANCICLOVIR; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ANEMIA; ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; BLEEDING; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; COVALENT BOND; CRYPTOCOCCAL MENINGITIS; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEVER; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HOSPITAL INFECTION; HUMAN; LEUKOPENIA; MALAISE; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCYTOPENIA; PATIENT MONITORING; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTI-INFECTIVE AGENTS; HUMANS; THROMBOCYTOPENIA;

EID: 84868517825     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328882     Document Type: Article

References (116)

1. Shehab N., Patel P. R., Srinivasan A., Budnitz D. S. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis: 2008; 47 6 735 743
2. van den Bemt P. M., Meyboom R. H., Egberts A. C. Drug-induced immune thrombocytopenia. Drug Saf: 2004; 27 15 1243 1252 (Pubitemid 40066085)
3. Prizola J. L., Smythe M. A., Dager W. E. Drug-induced thrombocytopenia in critically ill patients. Crit Care Med: 2010; 38 6 S145 S154
4. Veneri D., Franchini M., Randon F., Nichele I., Pizzolo G., Ambrosetti A. Thrombocytopenias: a clinical point of view. Blood Transfus: 2009; 7 2 75 85
5. Patel N., Vandewall H., Tristani L., et al. A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin. J Antimicrob Chemother: 2012; 67 3 725 735
6. Aster R. H., Bougie D. W. Drug-induced immune thrombocytopenia. N Engl J Med: 2007; 357 6 580 587 (Pubitemid 47236283)
7. George J. N., Raskob G. E., Shah S. R., et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med: 1998; 129 11 886 890 (Pubitemid 28549817)
8. George J. N., Aster R. H. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology (Am Soc Hematol Educ Program): 2009; 153 158
9. Kenney B., Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med: 2009; 133 2 309 314
10. Christie D. J., Mullen P. C., Aster R. H. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest: 1985; 75 1 310 314 (Pubitemid 15164000)
11. Smith M. E., Reid D. M., Jones C. E., Jordan J. V., Kautz C. A., Shulman N. R. Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest: 1987; 79 3 912 917 (Pubitemid 17050919)
12. Bougie D. W., Wilker P. R., Aster R. H. Patients with quinine-induced immune thrombocytopenia have both "drug-dependento" and "drug-specifico" antibodies. Blood: 2006; 108 3 922 927 (Pubitemid 44154626)
13. Warkentin T. E. Drug-induced immune-mediated thrombocytopeniafrom purpura to thrombosis. N Engl J Med: 2007; 356 9 891 893 (Pubitemid 46339907)
14. Visentin G. P., Liu C. Y. Drug-induced thrombocytopenia. Hematol Oncol Clin North Am: 2007; 21 4 685 696, vi (Pubitemid 47102560)
15. Bactrim D. S. [package insert]. Philadelphia, PA AR Scientific, Inc. September 2009
16. Aster R. H., Curtis B. R., McFarland J. G., Bougie D. W. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost: 2009; 7 6 911 918
17. Brown R. B., Klar J., Lemeshow S., Teres D., Pastides H., Sands M. Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med: 1986; 146 11 2159 2164 (Pubitemid 17189089)
18. Aitken P., Zaidi S. M. Cefuroxime-induced thrombocytopenia? Postgrad Med J: 1996; 72 854 757 758
19. Reichardt P., Handrick W., Linke A., Schille R., Kiess W. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatmenta retrospective analysis in 38 children with cystic fibrosis. Infection: 1999; 27 6 355 356
20. Ruiz-Irastorza G., Barreiro G., Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol: 1996; 95 4 611 612 (Pubitemid 26423361)
21. Salamon D. J., Nusbacher J., Stroupe T., Wilson J. H., Hanrahan J. B. Red cell and platelet-bound IgG penicillin antibodies in a patient with thrombocytopenia. Transfusion: 1984; 24 5 395 398 (Pubitemid 15202538)
22. Olivera E., Lakhani P., Watanakunakorn C. Isolated severe thrombocytopenia and bleeding caused by piperacillin. Scand J Infect Dis: 1992; 24 6 815 817 (Pubitemid 23047118)
23. Pérez-Vázquez A., Pastor J. M., Riancho J. A. Immune thrombocytopenia caused by piperacillin/tazobactam. Clin Infect Dis: 1998; 27 3 650 651 (Pubitemid 28422023)
24. Yan M. T., Chu H. Y., Chau T., Lin S. H. Profound thrombocytopenia associated with piperacillin in a hemodialysis patient. Clin Nephrol: 2009; 72 3 240 243
25. Grossjohan B., Eichler P., Greinacher A., Santoso S., Kroll H. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion: 2004; 44 7 1033 1040 (Pubitemid 38823810)
26. Fass R. J., Copelan E. A., Brandt J. T., Moeschberger M. L., Ashton J. J. Platelet-mediated bleeding caused by broad-spectrum penicillins. J Infect Dis: 1987; 155 6 1242 1248 (Pubitemid 17080501)
27. Bang N., Kammer R. Hematologic complications associated with B-lactam antibiotics. Rev Infect Dis: 1983; 5 02 S380 S393
28. Sakata H., Kakehashi H., Fujita K., Yoshioka H. Effects of aztreonam on fecal flora and on vitamin K metabolism. Antimicrob Agents Chemother: 1990; 34 6 1045 1047 (Pubitemid 20177352)
29. Agnelli G., Del Favero A., Parise P., et al. Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit? Antimicrob Agents Chemother: 1986; 29 6 1108 1109 (Pubitemid 16084081)
30. Zyvox [package insert]. Kalamazoo, MI Pharmacia & Upjohn Company: 2009
31. Attassi K., Hershberger E., Alam R., Zervos M. J. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis: 2002; 34 5 695 698 (Pubitemid 34165334)
32. Nasraway S. A., Shorr A. F., Kuter D. J., O'Grady N., Le V. H., Cammarata S. K. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis: 2003; 37 12 1609 1616 (Pubitemid 37549946)
33. Minson Q., Gentry C. A. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center. Pharmacotherapy: 2010; 30 9 895 903
34. Hogan H. L., Hachem R. Y., Neuhauser M., Raad I. I., Coyle E. Clinical experience of linezolid in bone marrow transplantation patients. J Pharm Pract: 2010; 23 4 352 357
35. Wu V. C., Wang Y. T., Wang C. Y., et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis: 2006; 42 1 66 72
36. Matsumoto K., Takeshita A., Ikawa K., et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents: 2010; 36 2 179 181
37. Spellberg B., Yoo T., Bayer A. S. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother: 2004; 54 4 832 835 (Pubitemid 39386741)
38. Plachouras D., Giannitsioti E., Athanassia S., et al. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis: 2006; 43 9 e89 e91
39. Bernstein W. B., Trotta R. F., Rector J. T., Tjaden J. A., Barile A. J. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother: 2003; 37 4 517 520 (Pubitemid 36389660)
40. Yu Z., Lennon V. A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med: 1999; 340 3 227 228 (Pubitemid 29063222)
41. Pascoalinho D., Vilas M. J., Coelho L., Moreira P. Linezolid-related immune-mediated severe thrombocytopenia. Int J Antimicrob Agents: 2011; 37 1 88 89
42. Rao N., Ziran B. H., Wagener M. M., Santa E. R., Yu V. L. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis: 2004; 38 8 1058 1064 (Pubitemid 38951248)
43. Shah R. A., Musthaq A., Khardori N. Vancomycin-induced thrombocytopenia in a 60-year-old man: a case report. J Med Case Reports: 2009; 3 7290
44. Govindarajan R., Baxter D., Wilson C., Zent C. Vancomycin-induced thrombocytopenia. Am J Hematol: 1999; 62 2 122 123
45. Lee J. H., Kim D. S., Lee H. S., Choi S. I., Cho Y. G. A case of vancomycin-induced thrombocytopenia. Korean J Hematol: 2009; 44 4 294 297
46. Kenney B., Tormey C. A. Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response. Platelets: 2008; 19 5 379 383
47. O'Donnell E., Shepherd C., Neff A. Immune thrombocytopenia from vancomycin in orthopedic cement. Am J Hematol: 2007; 82 12 1122 (Pubitemid 350209863)
48. Von Drygalski A., Curtis B. R., Bougie D. W., et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med: 2007; 356 9 904 910 (Pubitemid 46339909)
49. Myers M. W., Jick H. Hospitalization for serious blood and skin disorders following use of co-trimoxazole. Br J Clin Pharmacol: 1997; 43 4 446 448 (Pubitemid 27187486)
50. Yamreudeewong W., Fosnocht B. J., Weixelman J. M. Severe thrombocytopenia possibly associated with TMP/SMX therapy. Ann Pharmacother: 2002; 36 1 78 82 (Pubitemid 34052950)
51. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis: 1982; 4 2 426 428
52. Kaufman D. W., Kelly J. P., Johannes C. B., et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood: 1993; 82 9 2714 2718 (Pubitemid 23318077)
53. Pedersen-Bjergaard U., Andersen M., Hansen P. B. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol: 1998; 54 9-10 701 706 (Pubitemid 29024201)
54. Hagen M. D., White R. D. Thrombocytopenia secondary to trimethoprim-sulfamethoxazole. South Med J: 1983; 76 4 503 (Pubitemid 13126716)
55. Curtis B. R., McFarland J. G., Wu G. G., Visentin G. P., Aster R. H. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood: 1994; 84 1 176 183
56. Kiefel V., Santoso S., Schmidt S., Salama A., Mueller-Eckhardt C. Metabolite-specific (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprim-sulfamethoxazole-induced immune thrombocytopenia. Transfusion: 1987; 27 3 262 265 (Pubitemid 17087597)
57. Herrington A., Mahmood A., Berger R. Treatment options in sulfamethoxazole-trimethoprim-induced thrombocytopenic purpura. South Med J: 1994; 87 9 948 950 (Pubitemid 24295151)
58. Martínez E., Collazos J., Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore): 1999; 78 6 361 369 (Pubitemid 29534115)
59. Covic A., Goldsmith D. J., Segall L., et al. Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol Dial Transplant: 1998; 13 4 924 929 (Pubitemid 28161765)
60. Blajchman M. A., Lowry R. C., Pettit J. E., Stradling P. Rifampicin-induced immune thrombocytopenia. BMJ: 1970; 3 5713 24 26
61. Kakaiya R. M., Dehertogh D., Walker F. J., Cummings E., Uzdejczyk M. Rifampin-induced immune thrombocytopenia. A case report. Vox Sang: 1989; 57 3 185 187 (Pubitemid 19249894)
62. Mori M., Izawa K., Fujikawa T., et al. A case of acute and severe thrombocytopenia due to readministration of rifampicin. J Infect Chemother: 2011; 17 2 288 290
63. Martínez E., Muñiz E., Domingo P. Evidence implicating rifampin-independent antiplatelet antibodies in the pathogenesis of rifampin-induced immune thrombocytopenia. Clin Infect Dis: 1994; 19 2 351 353 (Pubitemid 24258947)
64. Burgess J. K., Lopez J. A., Gaudry L. E., Chong B. H. Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies. Blood: 2000; 95 6 1988 1992 (Pubitemid 30151636)
65. Pereira J., Hidalgo P., Ocqueteau M., et al. Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia. Br J Haematol: 2000; 110 4 907 910
66. Mehta Y. S., Jijina F. F., Badakere S. S., Pathare A. V., Mohanty D. Rifampicin-induced immune thrombocytopenia. Tuber Lung Dis: 1996; 77 6 558 562 (Pubitemid 27023156)
67. Hadfield J. W. Rifampicin-induced thrombocytopenia. Postgrad Med J: 1980; 56 651 59 60 (Pubitemid 10214691)
68. Pujet J. C., Homberg J. C., Decroix G. Sensitivity to rifampicin: incidence, mechanism, and prevention. BMJ: 1974; 2 5916 415 418
69. Levaquin [package insert]. Austin, TX Hospira, Inc. August: 2009
70. Cipro [package insert]. Wayne, NJ Bayer Healthcare Pharmaceuticals November: 2011
71. Avelox [package insert]. Wayne, NJ Bayer Healthcare Pharmaceuticals October: 2011
72. Salloum R., Liu C. Y., Weise A. M. Possible case of levofloxacin-induced thrombocytopenia. Am J Health Syst Pharm: 2011; 68 1 43 46
73. Cheah C. Y., De Keulenaer B., Leahy M. F. Fluoroquinolone-induced immune thrombocytopenia: a report and review. Intern Med J: 2009; 39 9 619 623
74. Chan C. S., Tuazon C. U., Lessin L. S. Amphotericin-B-induced thrombocytopenia. Ann Intern Med: 1982; 96 3 332 333 (Pubitemid 12187513)
75. Shigemi A., Matsumoto K., Ikawa K., et al. Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia. Int J Antimicrob Agents: 2011; 38 5 417 420
76. Sundar S., Chakravarty J., Agarwal D., Rai M., Murray H. W. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med: 2010; 362 6 504 512
77. Kulpa J., Zaroulis C. G., Good R. A., Kutti J. Altered platelet function and circulation induced by amphotericin B in leukemic patients after platelet transfusion. Transfusion: 1981; 21 1 74 76 (Pubitemid 12207716)
78. Hussein M. A., Fletcher R., Long T. J., Zuccaro K., Bolwell B. J., Hoeltge A. Transfusing platelets 2h after the completion of amphotericin-B decreases its detrimental effect on transfused platelet recovery and survival. Transfus Med: 1998; 8 1 43 47 (Pubitemid 28190197)
79. Slichter S. J., Davis K., Enright H., et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood: 2005; 105 10 4106 4114 (Pubitemid 40656162)
80. Sloand E. M., Kumar P., Yu M., Klein H. G. Effect of amphotericin B and fluconazole on platelet membrane glycoproteins. Transfusion: 1994; 34 5 415 420 (Pubitemid 24172379)
81. Kauffman C. A., Frame P. T. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother: 1977; 11 2 244 247 (Pubitemid 8042475)
82. Meyer R., Axelrod J. L. Fatal aplastic anemia resulting from flucytosine. JAMA: 1974; 228 12 1573
83. Stamm A. M., Diasio R. B., Dismukes W. E., et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med: 1987; 83 2 236 242
84. Shindo K., Mizuno T., Matsumoto Y., et al. Granulocytopenia and thrombocytopenia associated with combination therapy of amphotericin B and low-dose flucytosine in a patient with cryptococcal meningitis. DICP: 1989; 23 9 672 674 (Pubitemid 19231984)
85. Diasio R. B., Lakings D. E., Bennett J. E. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother: 1978; 14 6 903 908 (Pubitemid 9074641)
86. Harris B. E., Manning B. W., Federle T. W., Diasio R. B. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother: 1986; 29 1 44 48 (Pubitemid 16155219)
87. Mercurio M. G., Elewski B. E. Thrombocytopenia caused by fluconazole therapy. J Am Acad Dermatol: 1995; 32 3 525 526
88. Agarwal A., Sakhuja V., Chugh K. S. Fluconazole-induced thrombocytopenia. Ann Intern Med: 1990; 113 11 899
89. Sugar A. M., Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med: 1988; 85 4 481 489
90. Larsen R. A., Leal M. A., Chan L. S. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med: 1990; 113 3 183 187 (Pubitemid 20242293)
91. Costello C. Haematological abnormalities in human immunodeficiency virus (HIV) disease. J Clin Pathol: 1988; 41 7 711 715
92. Cancidas [package insert]. Whitehouse Station, NJ Merck & Co., Inc: 2010
93. Lynch J., Wong-Beringer A. Caspofungin: a potential cause of reversible severe thrombocytopenia. Pharmacotherapy: 2004; 24 10 1408 1411 (Pubitemid 39305003)
94. Eraxis [package insert]. New York, NY Pfizer: 2010
95. Mycamine [package insert]. Deerfield, IL Astellas Pharma US, Inc: 2011
96. Nazzal M., Safi F., Arma F., Nazzal M., Muzaffar M., Assaly R. Micafungin-induced thrombotic thrombocytopenic purpura: a case report and review of the literature. Am J Ther: 2011; 18 6 e258 e260
97. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant: 2004; 4 4 611 620 (Pubitemid 38523584)
98. Danziger-Isakov L., Mark Baillie G. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant: 2009; 23 3 295 304
99. Razonable R. R. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc: 2011; 86 10 1009 1026
100. Raisch D. W., Straight T. M., Holodniy M. Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature. Pharmacotherapy: 2009; 29 8 988 992
101. Brinker A. D., Beitz J. Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action. Am J Hematol: 2002; 70 4 313 317 (Pubitemid 34810509)
102. New risk management plan and patient medication guide for Qualaquin (quinine sulfate) [drug safety communication]. Rockville, MD: U.S. Food and Drug Administration; July 28, 2010 http://www.fda.gov.ezproxy.galter.northwestern. edu/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm218202.htm. Accessed February 15, 2012
103. Perdomo J., Yan F., Ahmadi Z., Jiang X. M., Stocker R., Chong B. H. Quinine-induced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. Blood: 2011; 117 22 5975 5986
104. Freiman J. P. Fatal quinine-induced thrombocytopenia. Ann Intern Med: 1990; 112 4 308 309 (Pubitemid 20055362)
105. Kunicki T. J., Russell N., Nurden A. T., Aster R. H., Caen J. P. Further studies of the human platelet receptor for quinine- and quinine-dependent antibodies. J Immunol: 1981; 126 2 398 402 (Pubitemid 11136682)
106. Yildiz B. O., Haznedarolu I. C., Cöplü L. Albendazole-induced amegakaryocytic thrombocytopenic purpura. Ann Pharmacother: 1998; 32 7-8 842
107. Fernández F. J., Rodríguez-Vidigal F. F., Ledesma V., Cabanillas Y., Vagace J. M. Aplastic anemia during treatment with albendazole. Am J Hematol: 1996; 53 1 53 54
108. Albenza [package insert]. Mississauga, Ontario, Canada GlaxoSmithKline: 2011
109. Kempin S. J., Jackson C. W., Edwards C. C. In vitro inhibition of platelet function and coagulation by pentamidine isethionate. Antimicrob Agents Chemother: 1977; 12 4 451 454 (Pubitemid 8192212)
110. Nebupent [package insert]. Schaumburg, IL APP Pharmaceuticals, LLC; December 2010
111. Sattler F. R., Cowan R., Nielsen D. M., Ruskin J. Trimethoprim- sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med: 1988; 109 4 280 287
112. Milder J. E., Walzer P. D., Powell R. D. Jr. Treatment of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole and pentamidine: efficacy and toxicity. South Med J: 1979; 72 12 1626 1628 (Pubitemid 10180707)
113. Christie D. J., Sauro S. C., Cavanaugh A. L., Kaplan M. E. Severe thrombocytopenia in an acquired immunodeficiency syndrome patient associated with pentamidine-dependent antibodies specific for glycoprotein IIb/IIIa. Blood: 1993; 82 10 3075 3080 (Pubitemid 23334934)
114. Reese J. A., Li X., Hauben M., et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood: 2010; 116 12 2127 2133
115. Rabinovitz M., Pitlik S. D., Halevy J., Rosenfeld J. B. Ethambutol-induced thrombocytopenia. Chest: 1982; 81 6 765 766 (Pubitemid 12073346)
116. Kant S., Verma S. K., Gupta V., Anand S. C., Prasad R. Pyrazinamide induced thrombocytopenia. Indian J Pharmacol: 2010; 42 2 108 109